FHTX

5.14

3.21% 0.16

Dopo l'orario di chiusura: 5.14

Foghorn Therapeutics Inc (FHTX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché FHTX Giù? Forum Previsione

Precedente Chiudi:

$4.98

Aprire:

$4.93

Volume 24 ore:

407.53K

Relative Volume:

2.53

Capitalizzazione di mercato:

$285.75M

Reddito:

$34.16M

Utile/perdita netta:

$-98.43M

Rapporto P/E:

-1.8759

EPS:

-2.74

Flusso di cassa netto:

$-119.33M

1 W Prestazione:

-3.02%

1M Prestazione:

-34.61%

6M Prestazione:

-1.91%

1 anno Prestazione:

-14.05%

Intervallo 1D:

$4.88

$5.28

Intervallo di 1 settimana:

$4.57

$5.6967

Portata 52W:

$2.70

$10.25

Foghorn Therapeutics Inc Stock (FHTX) Company Profile

Nome

Foghorn Therapeutics Inc

Settore

Healthcare (1176)

Industria

Biotechnology (673)

Telefono

617-586-3100

Indirizzo

500 TECHNOLOGY SQUARE, CAMBRIDGE

Dipendente

116

Cinguettio

Prossima data di guadagno

2024-11-04

Ultimi documenti SEC

FHTX's Discussions on Twitter

Confronta FHTX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
FHTX Foghorn Therapeutics Inc	5.14	285.75M	34.16M	-98.43M	-119.33M	-2.34
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-09-03	Iniziato	Jefferies	Buy
2024-08-19	Iniziato	Evercore ISI	Outperform
2023-03-28	Iniziato	BofA Securities	Buy
2023-01-05	Iniziato	BMO Capital Markets	Outperform
2021-11-22	Iniziato	H.C. Wainwright	Buy
2020-11-17	Iniziato	Cowen	Outperform
2020-11-17	Iniziato	Goldman	Buy
2020-11-17	Iniziato	Morgan Stanley	Overweight
2020-11-17	Iniziato	Wedbush	Outperform

Mostra tutto

Foghorn Therapeutics Inc Borsa (FHTX) Ultime notizie

Dec 20, 2024

FY2028 EPS Estimate for Foghorn Therapeutics Cut by Analyst - Defense World

Dec 20, 2024

HC Wainwright Has Positive Forecast for FHTX FY2024 Earnings - Defense World

Dec 20, 2024

Dec 19, 2024

Charles Schwab Investment Management Inc. Grows Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Dec 19, 2024

Wedbush Reduces Earnings Estimates for Foghorn Therapeutics - MarketBeat

Dec 19, 2024

HC Wainwright Issues Optimistic Estimate for FHTX Earnings - MarketBeat

Dec 19, 2024

Dec 18, 2024

Foghorn Therapeutics price target lowered to $13 from $20 at H.C. Wainwright - Yahoo Finance

Dec 18, 2024

Dec 17, 2024

Short Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Decreases By 9.7% - MarketBeat

Dec 17, 2024

Foghorn Therapeutics shares target cut, buy rating on positive outlook By Investing.com - Investing.com Canada

Dec 17, 2024

Foghorn Therapeutics (NASDAQ:FHTX) Given New $14.00 Price Target at Jefferies Financial Group - Defense World

Dec 17, 2024

Foghorn Therapeutics' (FHTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Dec 17, 2024

Foghorn Therapeutics Advances Precision Oncology Pipeline - Yahoo Finance

Dec 17, 2024

Dec 16, 2024

Foghorn Therapeutics' SWOT analysis: chromatin pioneer's stock faces pivotal moment - Investing.com Canada

Dec 16, 2024

Foghorn Therapeutics Stock Slides On Cancer Drug Development Halt, But Retail Remains Upbeat - MSN

Dec 16, 2024

Jefferies Financial Group Has Lowered Expectations for Foghorn Therapeutics (NASDAQ:FHTX) Stock Price - MarketBeat

Dec 16, 2024

Why Foghorn Therapeutics (FHTX) Stock Is Trading Lower - Benzinga

Dec 16, 2024

Foghorn Therapeutics Inc. Provides Update on FHD-286 Clinical Development Program and Strategic Priorities - Marketscreener.com

Dec 16, 2024

Foghorn shifts focus from AML drug FHD-286 - Investing.com

Dec 16, 2024

Foghorn Therapeutics Ends Solo Development of FHD-286 - MarketWatch

Dec 16, 2024

Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities - The Manila Times

Dec 16, 2024

Foghorn Therapeutics Halts Key AML Drug Development After Phase 1 Results Fall Short - StockTitan

Dec 16, 2024

Dec 13, 2024

After Plunging -30.17% in 4 Weeks, Here's Why the Trend Might Reverse for Foghorn Therapeutics (FHTX) - MSN

Dec 13, 2024

Dec 12, 2024

Wall Street Analysts See a 104.08% Upside in Foghorn Therapeutics (FHTX): Can the Stock Really Move This High? - MSN

Nov 26, 2024

Nov 19, 2024

(FHTX) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 19, 2024

Nov 18, 2024

Foghorn Therapeutics patents new CBP degradation inducers - BioWorld Online

Nov 18, 2024

Nov 13, 2024

Foghorn Therapeutics (FHTX) Collaborates with Eli Lilly and Surpasses Q3 Expectations - Nasdaq

Nov 13, 2024

Nov 12, 2024

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences - The Manila Times

Nov 12, 2024

Nov 08, 2024

(FHTX) Trading Report - Stock Traders Daily

Nov 08, 2024

What is HC Wainwright’s Estimate for FHTX FY2024 Earnings? - Defense World

Nov 08, 2024

Wedbush Lifts Earnings Estimates for Foghorn Therapeutics - Defense World

Nov 08, 2024

Nov 07, 2024

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think - Simply Wall St

Nov 07, 2024

Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Third-Quarter Report - Yahoo Finance

Nov 07, 2024

Research Analysts Issue Forecasts for FHTX FY2024 Earnings - MarketBeat

Nov 07, 2024

HC Wainwright Has Bullish Estimate for FHTX FY2024 Earnings - MarketBeat

Nov 07, 2024

Nov 06, 2024

We Think Foghorn Therapeutics (NASDAQ:FHTX) Needs To Drive Business Growth Carefully - Yahoo Finance

Nov 06, 2024